MedPath

Ciclopirox

Generic Name
Ciclopirox
Brand Names
Ciclodan, Cnl8, Loprox, Penlac, Stieprox
Drug Type
Small Molecule
Chemical Formula
C12H17NO2
CAS Number
29342-05-0
Unique Ingredient Identifier
19W019ZDRJ

Overview

Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.

Background

Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.

Indication

Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum.

Associated Conditions

  • Fungal skin infection
  • Pityriasis versicolor
  • Seborrheic dermatitis of the scalp
  • Tinea Corporis
  • Tinea Cruris
  • Tinea Pedis
  • Vulvovaginal Candidiasis
  • Cutaneous candidiasis
  • Mild Onychomycosis
  • Moderate Onychomycosis

FDA Approved Products

Ciclopirox
Manufacturer:Chartwell RX, LLC
Route:TOPICAL
Strength:71.3 mg in 1 mL
Approved: 2024/04/04
NDC:62135-814
CICLOPIROX 1% / CLOBETASOL PROPIONATE 0.05%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:1 g in 100 g
Approved: 2019/04/24
NDC:72934-7037
Ciclopirox
Manufacturer:Bryant Ranch Prepack
Route:TOPICAL
Strength:80 mg in 1 mL
Approved: 2023/08/17
NDC:72162-2076
CICLOPIROX
Manufacturer:Bryant Ranch Prepack
Route:TOPICAL
Strength:7.7 mg in 1 g
Approved: 2022/02/22
NDC:63629-8621
ciclopirox
Manufacturer:Glenmark Pharmaceuticals Inc., USA
Route:TOPICAL
Strength:7.7 mg in 1 g
Approved: 2017/01/13
NDC:68462-455

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath